Image

Breaking News

Featured image for “The FDA Just Approved a New Sunscreen Ingredient— What It Means for Patients with Skin Cancer, Survivors, and the General Public”
06/09/2026

The FDA Just Approved a New Sunscreen Ingredient— What It Means for Patients with Skin Cancer, Survivors, and the General Public

For anyone living with a history of skin cancer—or working to prevent it—sun protection shouldn’t be just a summer habit. That’s why today’s announcement from the…
Blog - Melanoma360
, 
Breaking News
Featured image for “Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA”
05/29/2026

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

WOBURN, Mass., May 29, 2026 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies,…
Blog - Melanoma360
, 
Breaking News
Featured image for “KIMMTRAK doubles the likelihood of being alive at five years for firstline HLA-A*02:01+ patients with metastatic uveal melanoma”
04/19/2026

KIMMTRAK doubles the likelihood of being alive at five years for firstline HLA-A*02:01+ patients with metastatic uveal melanoma

OS benefit observed across key subgroups, including patients with high tumor burden, elevated LDH, and extrahepatic disease as well as…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “FDA Does Not Approve RP1 in Combination with Nivolumab for Advanced Melanoma: What This Means for Patients”
04/10/2026

FDA Does Not Approve RP1 in Combination with Nivolumab for Advanced Melanoma: What This Means for Patients

On April 10, 2026, the U.S. Food and Drug Administration (FDA) issued a decision not to approve the resubmission of…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “Merlin CP-GEP Becomes the First and Only Gene Expression Profile Test Recommended by NCCN® ”
02/19/2026

Merlin CP-GEP Becomes the First and Only Gene Expression Profile Test Recommended by NCCN® 

San Diego, CA & Rotterdam, Netherlands- February 19, 2026 — SkylineDx today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma”
02/05/2026

Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma

52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control Rate SAN CARLOS, Calif., Feb.…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “SkylineDx Publishes Landmark MERLIN_001 Trial in JAMA Surgery Validating the Predictive Power of the Merlin CP-GEP Test in Melanoma”
10/22/2025

SkylineDx Publishes Landmark MERLIN_001 Trial in JAMA Surgery Validating the Predictive Power of the Merlin CP-GEP Test in Melanoma

Rotterdam, The Netherlands – San Diego, CA – [October 22nd] – SkylineDx today announced that results from its landmark MERLIN_001…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma”
10/20/2025

Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma

Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026   WOBURN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) — Replimune…
Blog - Melanoma360
, 
Breaking News
Featured image for “Remembering Brandon Blackstock: A Call to Action on Melanoma Awareness”
08/12/2025

Remembering Brandon Blackstock: A Call to Action on Melanoma Awareness

Difficult News and A Reminder of the Impact of Melanoma Today we would like to acknowledge the recent death of…
Blog - Melanoma360
, 
Breaking News
Featured image for “IO Biotech Announces Phase 3 Results for Cylembio® + KEYTRUDA® in Advanced Melanoma”
08/11/2025

IO Biotech Announces Phase 3 Results for Cylembio® + KEYTRUDA® in Advanced Melanoma

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT) today announces topline results from the pivotal Phase…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
06/09/2026

The FDA Just Approved a New Sunscreen Ingredient— What It Means for Patients with Skin Cancer, Survivors, and the General Public

For anyone living with a history of skin cancer—or working to prevent it—sun protection shouldn’t be just a summer habit. That’s why today’s announcement from the…
Featured image for “The FDA Just Approved a New Sunscreen Ingredient— What It Means for Patients with Skin Cancer, Survivors, and the General Public”
Blog - Melanoma360
 | 
Breaking News
05/29/2026

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

WOBURN, Mass., May 29, 2026 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies,…
Featured image for “Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA”
Blog - Melanoma360
 | 
Breaking News
04/19/2026

KIMMTRAK doubles the likelihood of being alive at five years for firstline HLA-A*02:01+ patients with metastatic uveal melanoma

OS benefit observed across key subgroups, including patients with high tumor burden, elevated LDH, and extrahepatic disease as well as…
Featured image for “KIMMTRAK doubles the likelihood of being alive at five years for firstline HLA-A*02:01+ patients with metastatic uveal melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
04/10/2026

FDA Does Not Approve RP1 in Combination with Nivolumab for Advanced Melanoma: What This Means for Patients

On April 10, 2026, the U.S. Food and Drug Administration (FDA) issued a decision not to approve the resubmission of…
Featured image for “FDA Does Not Approve RP1 in Combination with Nivolumab for Advanced Melanoma: What This Means for Patients”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
02/19/2026

Merlin CP-GEP Becomes the First and Only Gene Expression Profile Test Recommended by NCCN® 

San Diego, CA & Rotterdam, Netherlands- February 19, 2026 — SkylineDx today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its…
Featured image for “Merlin CP-GEP Becomes the First and Only Gene Expression Profile Test Recommended by NCCN® ”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
02/05/2026

Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma

52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control Rate SAN CARLOS, Calif., Feb.…
Featured image for “Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
10/22/2025

SkylineDx Publishes Landmark MERLIN_001 Trial in JAMA Surgery Validating the Predictive Power of the Merlin CP-GEP Test in Melanoma

Rotterdam, The Netherlands – San Diego, CA – [October 22nd] – SkylineDx today announced that results from its landmark MERLIN_001…
Featured image for “SkylineDx Publishes Landmark MERLIN_001 Trial in JAMA Surgery Validating the Predictive Power of the Merlin CP-GEP Test in Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
10/20/2025

Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma

Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026   WOBURN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) — Replimune…
Featured image for “Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma”
Blog - Melanoma360
 | 
Breaking News
08/12/2025

Remembering Brandon Blackstock: A Call to Action on Melanoma Awareness

Difficult News and A Reminder of the Impact of Melanoma Today we would like to acknowledge the recent death of…
Featured image for “Remembering Brandon Blackstock: A Call to Action on Melanoma Awareness”
Blog - Melanoma360
 | 
Breaking News
08/11/2025

IO Biotech Announces Phase 3 Results for Cylembio® + KEYTRUDA® in Advanced Melanoma

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT) today announces topline results from the pivotal Phase…
Featured image for “IO Biotech Announces Phase 3 Results for Cylembio® + KEYTRUDA® in Advanced Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research

Recent Posts

Featured image for “The FDA Just Approved a New Sunscreen Ingredient— What It Means for Patients with Skin Cancer, Survivors, and the General Public”
Jun. 09, 2026

The FDA Just Approved a New Sunscreen Ingredient— What It Means for Patients with Skin Cancer, Survivors, and the General Public

Featured image for “Fifth Annual Evening in Memory of Valerie Guild”
Jun. 05, 2026

Fifth Annual Evening in Memory of Valerie Guild

Featured image for “Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective ”
Jun. 05, 2026

Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective 

Featured image for “Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes”
Jun. 05, 2026

Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes

Featured image for “Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors”
Jun. 05, 2026

Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors

Filter by Tag